Side-by-side · Research reference

DSIPvsTeriparatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED8/36 cited

BFDA-ApprovedHUMAN-REVIEWED10/62 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

01Mechanism of Action

Parameter

DSIP

Teriparatide

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Feedback intact?

—

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Antibody development

—

02Dosage Protocols

Parameter

DSIP

Teriparatide

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

—

Frequency

Once daily, pre-sleep

Once daily

Intermittent administration preserves anabolic effect.

Lower / starter dose

50 mcg pre-sleep

—

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

RCT / FDA-approved

Duration

8–12 weeks per cycle

—

Reconstitution

Bacteriostatic water

—

Timing

30–60 min pre-sleep

Morning or evening (flexible)

Half-life

Short plasma; CNS effects last hours

—

Standard dose (osteoporosis)

—

20 mcg / day

FDA-approved regimen for severe osteoporosis.

Maximum duration

—

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

Hypoparathyroidism dose

—

20 mcg / day

Used off-label for chronic hypoparathyroidism.

Pelvic fragility fractures

—

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

Route

—

Subcutaneous (thigh or abdomen)

Storage

—

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

Pharmacogenetics

—

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

03Metabolic / Fat Loss Evidence

Parameter

DSIP

Teriparatide

Fat loss application

—

None — teriparatide is a bone anabolic agent without direct lipolytic activity

04Side Effects & Safety

Parameter

DSIP

Teriparatide

Injection site reaction

Mild irritation

Erythema, bruising, pain (uncommon)

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

—

Pregnancy / OB

Avoid

—

Hypercalcemia

—

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

Orthostatic hypotension

—

Dizziness, lightheadedness within hours of injection

Nausea

—

Common, usually mild and transient

Leg cramps / Arthralgia

—

Musculoskeletal pain reported in clinical trials

Hypercalciuria

—

Increased urinary calcium excretion; monitor for nephrolithiasis risk

Osteosarcoma (black box warning)

—

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

05Administration Protocol

Parameter

DSIP

Teriparatide

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

2. Injection site

SQ — abdomen. Rotate sites.

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

3. Timing

30–60 min pre-sleep.

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

5. Needle

29–31G insulin syringe.

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

6. Calcium and vitamin D supplementation

—

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.